BMC Medicine

CORRECTION

Open Access

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

Chengming Liu[1,2†], Lu Yang[3,4†], Haiyan Xu[5†], Sufei Zheng[1,2], Zhanyu Wang[1,2], Sihui Wang[1,2], Yaning Yang[4], Shuyang Zhang[4], Xiaoli Feng[6], Nan Sun[1,2*], Yan Wang[4*] and Jie He[1,2*]

Correction: BMC Med 20, 187 (2022)
https://doi.org/10.1186/s12916-022-02356-7

After publication of the original article [1], it came to the authors' attention that there is an error in the originally-published version of **Additional file 1: Table S2 and Table S3**. In the univariate and multivariate regression analyses of the association between baseline plasma or tumor tissue IL-6 levels and clinical factors for the prediction of progression-free survival (PFS), the results of smoking history were lost.

The correct version of **Additional file 1: Table S2 and Table S3** is published in this erratum.

The original article can be found online at https://doi.org/10.1186/s12916-022-02356-7.

†Chengming Liu, Lu Yang and Haiyan Xu contributed equally to this work.

*Correspondence: sunnan@vip.126.com; wangyanyifu@163.com; prof.jiehe@gmail.com

[2] State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

[4] Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Full list of author information is available at the end of the article

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02492-0.

Additional file 1: Table S2. Univariate and multivariate regression analyses of the association between baseline plasma IL-6 levels and clinical factors for the prediction of PFS. **Table S3.** Univariate and multivariate regression analyses of the relationship between baseline tumor tissue IL-6 levels and clinical factors for the prediction of PFS.

Author details

[1]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [2]State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [3]Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China. [4]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [5]Department of Comprehensive Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [6]Department of Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Published online: 26 July 2022

Reference

1. Liu C, Yang L, Xu H, Zheng S, Wang Z, Wang S, et al. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Med. 2022;20(1):187. https://doi.org/10.1186/s12916-022-02356-7.